Mersana Therapeutics Valuation
| MRSN Stock | USD 0.62 0.01 1.64% |
Mersana Therapeutics is overvalued. Mersana Therapeutics secures a last-minute Real Value of $0.6 per share. The latest price of the firm is $0.62. Our model forecasts the value of Mersana Therapeutics from analyzing the firm fundamentals such as Return On Equity of -2.13, profit margin of (2.14) %, and Current Valuation of (47.77 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Mersana Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Mersana Therapeutics is based on 3 months time horizon. Increasing Mersana Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Mersana Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mersana Stock. However, Mersana Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.62 | Real 0.6 | Hype 0.58 |
The intrinsic value of Mersana Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mersana Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mersana Therapeutics helps investors to forecast how Mersana stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mersana Therapeutics more accurately as focusing exclusively on Mersana Therapeutics' fundamentals will not take into account other important factors: Mersana Therapeutics Total Value Analysis
Mersana Therapeutics is now projected to have valuation of (47.77 M) with market capitalization of 75.9 M, debt of 33.83 M, and cash on hands of 225.13 M. The negative valuation of Mersana Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Mersana Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(47.77 M) | 75.9 M | 33.83 M | 225.13 M |
Mersana Therapeutics Investor Information
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.6. Mersana Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Mersana Therapeutics' liquidity, profitability, solvency, and operating efficiency, Mersana Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Mersana Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Mersana Therapeutics has an asset utilization ratio of 16.3 percent. This suggests that the Company is making $0.16 for each dollar of assets. An increasing asset utilization means that Mersana Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Mersana Therapeutics Ownership Allocation
The majority of Mersana Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mersana Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mersana Therapeutics. Please pay attention to any change in the institutional holdings of Mersana Therapeutics as this could imply that something significant has changed or is about to change at the company.Mersana Therapeutics Profitability Analysis
The company reported the previous year's revenue of 36.85 M. Net Loss for the year was (171.67 M) with loss before overhead, payroll, taxes, and interest of (113.43 M).About Mersana Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Mersana Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Mersana Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Mersana Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Mersana Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mersana Therapeutics. We calculate exposure to Mersana Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mersana Therapeutics's related companies.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates for cancer patients with unmet need. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Mersana Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 169 people.
Mersana Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 116.1 M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.